ADC Therapeutics raises USD 60 million to strengthen oncology portfolio
Life sciences
21 October 2025
ADC Therapeutics’ antibody-drug conjugates (ADCs) deliver targeted cancer therapy by combining monoclonal antibodies with potent cytotoxic agents. | © ADC Therapeutics
Lausanne-based biotech ADC Therapeutics has secured USD 60 million in new financing to expand commercialization of its cancer treatment ZYNLONTA.
ADC Therapeutics, a global pioneer in the field of antibody-drug conjugates (ADCs), has announced a USD 60 million private investment in public equity (PIPE) financing to support its next phase of growth. Based at the Biopôle life sciences campus in Lausanne, the company is advancing a portfolio of targeted oncology therapies designed to improve outcomes for patients with difficult-to-treat cancers.
The financing round is led by TCGX, with participation from Redmile Group and other existing investors. ADC Therapeutics will issue 11.3 million common shares at USD 4.00 per share and 3.8 million pre-funded warrants at USD 3.90 each. The transaction, expected to close on October 27, 2025, will provide the company with approximately USD 57.6 million in net proceeds after expenses.
The funds will be used to support the commercial expansion of ZYNLONTA®, ADC Therapeutics’ FDA- and EMA-approved treatment for relapsed or refractory large B-cell lymphoma, and to strengthen the company’s financial position ahead of a potential relaunch in 2027. “This financing enhances our ability to prepare for and execute the potential relaunch of ZYNLONTA and further strengthens our balance sheet,” said Ameet Mallik, CEO of ADC Therapeutics. “We believe we are well-positioned to accelerate our trajectory towards long-term sustainable growth.”
A hub for advanced cancer research and precision medicine
ZYNLONTA, the company’s lead product, is the first and only CD19-directed ADC approved for adult patients who have received two or more prior lines of therapy. By combining an antibody targeting B-cell surface proteins with a potent cytotoxic payload, ZYNLONTA delivers targeted cancer cell destruction while minimizing off-target effects.
Founded in 2011 and headquartered in the canton of Vaud, ADC Therapeutics exemplifies Western Switzerland’s strength in oncology innovation. Its presence within the Biopôle ecosystem, home to a growing cluster of biotech and medtech companies, continues to reinforce the region’s reputation as a European hub for advanced cancer research and precision medicine.
